SSY Group (Stock Code: 2005) has issued a profit warning for the year ended 31 December 2025. According to preliminary estimates based on unaudited management accounts, profit attributable to equity shareholders is expected to decrease by 45% to 60% compared to the HK$1.06 billion recorded in 2024.

The announcement cites a decline in turnover as the primary factor driving the anticipated profit reduction. Major challenges include the absence of large-scale influenza outbreaks in the People’s Republic of China during 2025, tighter control of medical insurance costs, intensified pricing pressure due to expanding volume-based procurement schemes, and reduced sales of Bromhexine Hydrochloride in ampoule injection. Despite market headwinds, the company highlights its stable financial position and continued efforts to diversify its product range, with growing emphasis on oral preparations and bulk pharmaceutical products. The final audited figures, along with further details, will be disclosed in the forthcoming annual results announcement and report.